Marwah Karim

The paper develops pyrazolopyrimidine-based macrocyclic kinase inhibitors targeting AAK1, showing selectivity over related NAK family members and antiviral activity against RNA viruses.

RMC-113 inhibits PIP4K2C and PIKfyve, reversing SARS-CoV-2-induced autophagic flux impairment and showing antiviral effects.

The paper optimizes a 2-aminopyrimidine-based macrocycle to create a dual EPHA2/GAK kinase inhibitor with antiviral activity against dengue virus.

The paper designs a new class of protease inhibitors targeting coronavirus Mpro, identifying ML1000 as a potent inhibitor with low-nanomolar affinity and antiviral activity.